AI ScreeningAI ChatPricing
  1. JP-listed companies
  2. SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.
  3. Financials
  4. Repayments of term debt

SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.【JP:2395】

Market cap
¥64.4B
P/E ratio
18.1x
Provides drug development testing services to pharmaceutical companies and operates innovative intranasal drug delivery technology through spinout companies.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndRepayments of term debt (Million JPY)YoY (%)
Mar 31, 2025-8,826+41.67%
Mar 31, 2024-6,230+13.94%
Mar 31, 2023-5,468+56.58%
Mar 31, 2022-3,492-24.05%
Mar 31, 2021-4,598+10.35%
Mar 31, 2020-4,167-11.49%
Mar 31, 2019-4,708-19.43%
Mar 31, 2018-5,843-12.24%
Mar 31, 2017-6,658+0.11%
Mar 31, 2016-6,650-0.86%
Mar 31, 2015-6,708

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)